Fibrosis is a major subject of drug discovery and clinical translation, but quantitative and translational pharmacodynamic biomarkers are lacking. Non-invasive imaging is being used to fill this gap. In particular, MRI and CT—being highly sensitive to tissue structure and density—can provide quantitative readouts for fibrosis in organs, among them kidney, lung, and liver.
For example, the pathogenesis of chronic kidney disease (CKD) is characterized by progressive decline of renal function and accumulation of extracellular matrix, which leads to a diffuse fibrosis. MRI-based apparent water diffusion imaging—as shown in studies and in work done at MI Bioresearch—can sensitively detect the presence of hypercellularity that progresses in the rodent models of CKD. Importantly, this readout can be translated clinically, enabling non-invasive and quantitative endpoints that provide better specificity than traditional measures.
Contact us to discuss using imaging study designs to test fibrosis targeted therapeutics in kidney, lung, and liver models.